These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29914955)

  • 1. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
    Rhee EG; Rizk ML; Calder N; Nefliu M; Warrington SJ; Schwartz MS; Mangin E; Boundy K; Bhagunde P; Colon-Gonzalez F; Jumes P; Liu Y; Butterton JR
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
    Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
    J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
    Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR; Rybak JM; Claeys KC
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
    J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA
    Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
    Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
    Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
    Bhagunde P; Colon-Gonzalez F; Liu Y; Wu J; Xu SS; Garrett G; Jumes P; Lasseter K; Marbury T; Rizk ML; Lala M; Rhee EG; Butterton JR; Boundy K
    Br J Clin Pharmacol; 2020 May; 86(5):944-957. PubMed ID: 31856304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
    Roberts JA; Nicolau DP; Martin-Loeches I; Deryke CA; Losada MC; Du J; Patel M; Rizk ML; Paschke A; Chen LF
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad011. PubMed ID: 36880088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
    Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
    Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
    Fratoni AJ; Mah JW; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2022 Oct; 77(11):2992-2999. PubMed ID: 35906810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
    Rhee EG; Rizk ML; Calder N; Nefliu M; Warrington SJ; Schwartz MS; Mangin E; Boundy K; Bhagunde P; Colon-Gonzalez F; Jumes P; Liu Y; Butterton JR
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30478180
    [No Abstract]   [Full Text] [Related]  

  • 20. Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications.
    Ghazi IM; El Nekidy WS; Sood A; Dulku A; Patel R; Patel K; Li P
    Clin Ther; 2020 Mar; 42(3):475-485. PubMed ID: 32139175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.